Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Weighing benefits and risks--the FDA's review of prasugrel.

Unger EF.

N Engl J Med. 2009 Sep 3;361(10):942-5. doi: 10.1056/NEJMp0907122. No abstract available.

PMID:
19726770
2.

Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.

Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, Malhotra S.

Br J Clin Pharmacol. 2009 Jul;68(1):4-13. doi: 10.1111/j.1365-2125.2009.03402.x.

3.

Hypercholesterolemia-associated endothelial progenitor cell dysfunction.

Pirro M, Bagaglia F, Paoletti L, Razzi R, Mannarino MR.

Ther Adv Cardiovasc Dis. 2008 Oct;2(5):329-39. doi: 10.1177/1753944708094769. Review.

PMID:
19124431
4.

Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S.

J Am Coll Cardiol. 2008 Sep 30;52(14):1134-40. doi: 10.1016/j.jacc.2008.07.006.

5.

Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden.

Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW.

J Am Coll Cardiol. 2007 Aug 14;50(7):573-83.

6.

Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.

Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R.

Circulation. 2007 May 8;115(18):2435-41.

7.

Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.

Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R.

Circulation. 2007 Feb 27;115(8):1051-8. Review.

8.

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.

Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW.

Lancet. 2007 Feb 24;369(9562):667-78.

PMID:
17321312
9.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB.

N Engl J Med. 2007 Mar 8;356(10):998-1008.

10.

Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.

Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group..

N Engl J Med. 2007 Mar 8;356(10):1009-19.

11.

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators..

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91.

12.

Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.

Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M.

Eur Heart J. 2007 Apr;28(8):961-7.

13.

Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.

Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S.

J Am Coll Cardiol. 2006 May 16;47(10):2108-11. Review.

14.

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A.

JAMA. 2005 May 4;293(17):2126-30.

PMID:
15870416
15.

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators..

N Engl J Med. 2004 Jan 15;350(3):221-31.

16.

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators..

N Engl J Med. 2003 Oct 2;349(14):1315-23.

17.

Pathological mechanisms of fatal late coronary stent thrombosis in humans.

Farb A, Burke AP, Kolodgie FD, Virmani R.

Circulation. 2003 Oct 7;108(14):1701-6.

Items per page

Supplemental Content

Support Center